大うつ病性障害：主要8ヶ国市場における薬剤予測と市場分析- 最新情報

大うつ病性障害（MDD）は、世界で最も一般的な精神疾患の1つであり、単発または反復性の大うつ病エピソード（MDE）を特徴とします。うつ病のエピソードは、経験した症状の数と重症度に基づいて、軽度、中等度、または重度に分類されます。さらに、各重症度における患者のサブセットは治療抵抗性として分類され、典型的には、患者が少なくとも2回の抗うつ薬治療に反応しない場合です。MDDは再発性の疾患であり、多くの患者にとって、最初のうつ病エピソードは、心理社会的機能に重大な障害を伴う再発性の衰弱性慢性疾患へと発展します。

MDDの管理には、患者が最初に治療を受けたときから抑うつ症状が寛解するまでの急性短期療法と、完全かつ持続的で機能的な回復を可能にする試みとともに症状の再発を予防することを目的とした長期維持療法が含まれます。MDDの治療には幅広い種類の抗うつ薬が使用可能であり、抗うつ薬による治療を強化するために追加できる他の薬剤もあります。

当レポートでは、大うつ病性障害（MDD）市場について調査し、疾患概要、疫学、疾患管理、競合評価、アンメットニーズ、研究開発戦略、現在および将来の参入企業、市場展望など、詳細な内容をまとめています。

目次

第1章 大うつ病性障害：エグゼクティブサマリー

第2章 イントロダクション

第3章 疾患の概要

第4章 疫学

第5章 疾病管理

第6章 競争力評価

第7章 アンメットニーズと機会の評価

第8章 研究開発戦略

第9章 パイプライン評価

第10章 パイプライン評価分析

第11章 現在および将来の参入企業

第12章 市場の見通し

第13章 付録

List of Tables

List of Tables

• Table 1: MDD: Key metrics in the 8MM
• Table 2: DSM-V criteria of major depressive episode
• Table 3: ICD-10 criteria of major depressive episode
• Table 4: Subtypes of major depressive episode
• Table 5: Risk factors and comorbidities for MDD
• Tabl

List of Figures

List of Figures

• Figure 1: Global sales forecast by country for MDD in 2019 and 2029
• Figure 2: Analysis of the company portfolio gap in MDD during the forecast period
• Figure 3: Overview of targets of antidepressant action on noradrenergic and serotonergic

Abstract

The report provides an in-depth assessment of the MDD market including disease overview, epidemiology, disease management, competitive assessment, unmet needs, R&D strategies, current and future players, and market outlook.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). Episodes of depression can be classified as mild, moderate, or severe, based on the number and severity of symptoms experienced. In addition, a subset of patients in each severity can be classified as being treatment-resistant, typically when patients do not respond to at least two antidepressant treatments. MDD is a recurrent disorder, and for many patients, an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant impairments in psychosocial functioning.

The management of MDD involves acute, short-term therapy from when patients are initially provided treatment until remission of their depressive symptoms, and long-term maintenance treatment aimed at preventing the recurrence of symptoms with an attempt to enable a full, lasting, and functional recovery. There is a wide range of antidepressants available to treat MDD, as well as a variety of other drugs that can be added on to boost treatment with antidepressants.

Key Highlights

• Forecast includes the 8 major markets (8MM)
• Forecast covers the period 2019-2029

Scope

• Overview of major depressive disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
• Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three adult patient segments (mild, moderate, and severe) from 2019 to 2029.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD therapy. The most promising candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Major Depressive Disorder: Executive Summary - Updated Nov 2023, based on events up to Oct 31, 2023

2. Introduction - Updated Nov 2023, based on events up to Oct 31, 2023

3. Disease Overview - Updated Nov 2023, based on events up to Oct 31, 2023

4. Epidemiology

5. Disease Management - Updated Nov 2023, based on events up to Oct 31, 2023

6. Competitive Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

7. Unmet Needs and Opportunity Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

8. R&D Strategies - Updated Nov 2023, based on events up to Oct 31, 2023

9. Pipeline Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

10. Pipeline Valuation Analysis - Updated Nov 2023, based on events up to Oct 31, 2023

11. Current and Future Players - Updated Nov 2023, based on events up to Oct 31, 2023

12. Market Outlook - Updated Nov 2023, based on events up to Oct 31, 2023

13. Appendix - Updated Apr 2023, based on events up to Apr 13, 2023